Arzneimittelforschung 2008; 58(6): 283-287
DOI: 10.1055/s-0031-1296508
Anticoagulants · Antithrombotics · Antivaricosis Drugs · Blood Flow Stimulants
Editio Cantor Verlag Aulendorf (Germany)

Bioequivalence of Two Oral Formulations of Triflusal Capsules in Healthy Volunteers

Emilio García Quetglas
Clinical Research Unit, Clínica Universitaria de Navarra, Universidad de Navarra, Pamplona, Spain
,
Miguel Angel Campanero
Clinical Research Unit, Clínica Universitaria de Navarra, Universidad de Navarra, Pamplona, Spain
,
Belén Sádaba
Clinical Research Unit, Clínica Universitaria de Navarra, Universidad de Navarra, Pamplona, Spain
,
Manuel Escolar
Clinical Research Unit, Clínica Universitaria de Navarra, Universidad de Navarra, Pamplona, Spain
,
Jose Ramón Azanza
Clinical Research Unit, Clínica Universitaria de Navarra, Universidad de Navarra, Pamplona, Spain
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
15. Dezember 2011 (online)

Abstract

Triflusal (CAS 322-79-2) is an antiplatelet agent related to salicylates used in several European and Latin American countries in the treatment of cardiovascular diseases. The aim of this paper was to evaluate the bioequivalence of triflusal derived from two preparations using both parent drug and metabolite pharmacokinetic data.

The bioavailability was measured in 24 healthy male Caucasian volunteers following a single oral dose (600 mg) of the test or reference products in the fasting state. Blood samples were collected for 120 h. Plasma concentrations of triflusal and its metabolite 3-hydroxy-4-trifluoromethylbenzoic acid (HTB) were analyzed by high-performance liquid chromatography with UV and fluorescence detection, respectively. The non-compart-mental method was used for pharmaco-kinetic analysis. Log-transformed Cmax, AUC0-t and AUC0-∞ were tested for bioequivalence using ANOVA and Schuirmann’s two-one sided t-test. Tmax was analyzed by nonparametric pharmacokinetic parameters of triflusal and HTB derived from the two formulations were nearly consistent with previous observations. Triflusal parameters derived from the test and reference drug were as follows: Cmax (16.85 ± 11.41 vs 14.48 ± 7.22 mg/l), AUC0-t (18.43 ± 10.91 vs 16.22 ± 7.58 mg/l per hour), Tmax (1 range 0.25–2h vs 0.875 range 0.25–1.5 h), and t1/2 (0.49 ± 00.27 vs 0.76 ± 0.64). HTB parameters after test and reference formulation administration were as follows: Cmax (68.13 ± 23.05 vs 65.51 ± 19.44 mg/l), AUC0-t (2748.18 ± 971.91 vs 2877.97 ± 881.2 h ∙ mg/l), AUC0-∞ (3350.15 ± 1182.62 vs 3372.49 ± 1110.35 h ∙ mg/l), Tmax (2 range 1–10 h vs 2 range 0.75-12 h), and t1/2 (42.19 ± 7.82 vs 43.13 ± 6.56 h). 90 % of confidence intervals for the test/reference ratio of Cmax, AUC0–t and AUC0–∞ derived from both triflusal and HTB were found within the range of 80 %–125 % acceptable for bioequivalence. No significant difference was found between the Tmax values for triflusal and HTB.

It was concluded that the two preparations are bioequivalent and may be prescribed interchangeably.

 
  • References

  • 1 McNeely W, Goa KL. Triflusal. Drugs. 1998; 55: 823-833 discussion 834–825
  • 2 Ramis J, Mis R, Forn J, Torrent J, Gorina E, Jane F. Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. Eur J Drug Metab Pharmacokinet. 1991; 16: 269-273
  • 3 Ferrari E, Reboldi G, Marenco P, D’Angelo L, Crema F, Ambrosoli L et al Pharmacokinetic Study of Triflusal in Elderly Subjects After Single and Repeated Oral Administration. Am J Ther. 1996; 3: 630-636
  • 4 Ramis J, Torrent J, Mis R, Conte L, Barbanoj MJ, Jane J et al Pharmacokinetics of triflusal after single and repeated doses in man. Int J Clin Pharmacol Ther Toxicol. 1990; 28: 344-349
  • 5 EMEA (European Agency for the Evaluation of Medicinal Products). CPMP (Committee for Propietary Medicinal Products). Note for guidance on the investigation of bioavailability and bioequivalence. London, July 2001.
  • 6 Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther. 1990; 28: 272-287
  • 7 Steinijans VW, Diletti E. Generalization of distribution-free confidence intervals for bioavailability ratios. Eur J Clin Pharmacol. 1985; 28: 185-188
  • 8 Chen ML, Lee SC, Ng MJ, Schuirmann DJ, Lesko LJ, Williams RL. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther. 2000; 68: 510-521
  • 9 Cho HY, Jeong TJ, Lee YB. Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography. J Chromatogr B. 2003; 798: 257-264
  • 10 FDA CEDER. March 2003. Guidance for industry. Bioavailability and Bioequivalence studies for orally administered drug products. General considerations.